Objectives. To evaluate clinical, laboratory, and radiological variables from preoperative contrast-enhanced computed tomography (CECT) for their ability to distinguish ovarian clear cell carcinoma (OCCC) from nonOCCC and to develop a nomogram to preoperatively predict the probability of OCCC.Methods. This IRB-approved, retrospective study included consecutive patients who underwent surgery for an ovarian tumor from 1/1/2000 to 12/31/2016 and CECT of the abdomen and pelvis & LE;90 days before primary debulking surgery. Using a standardized form, two experienced oncologic radiologists independently analyzed imaging features and provided a subjective 5-point impression of the probability of the histological diagnosis. Nomogram models incorporating clinical, laboratory, and radiological features were created to predict histological diagnosis of OCCC over non-OCCC. Results. The final analysis included 533 patients with surgically confirmed OCCC (n = 61) and non-OCCC (n = 472); history of endometriosis was more often found in patients with OCCC (20% versus 3.6%; p < 0.001), while CA-125 was significantly higher in patients with non-OCCC (351 ng/mL versus 70 ng/mL; p < 0.001). A nomogram model incorporating clinical (age, history of endometriosis and adenomyosis), laboratory (CA-125) and imaging findings (peritoneal implant distribution, morphology, laterality, and diameter of ovarian lesion and of the largest solid component) had an AUC of 0.9 (95% CI: 0.847, 0.949), which was comparable to the AUCs of the experienced radiologists' subjective impressions [0.8 (95% CI: 0.822, 0.891) and 0.9 (95% CI: 0.865, 0.936)].Conclusions. A presurgical nomogram model incorporating readily accessible clinical, laboratory, and CECT variables was a powerful predictor of OCCC, a subtype often requiring a distinctive treatment approach. & COPY; 2023 Elsevier Inc. All rights reserved.

Background Subtle neurodegenerative motor and cognitive impairments accumulate over a prodromal period several years before clinical diagnosis of Huntington's disease (HD). The inclusion of prodromal individuals in therapeutic trials would facilitate testing of therapies early in the disease course and the development of treatments intended to prevent or delay disability. Objectives We evaluate the normalized prognostic index (PIN) score as a tool to select participants for a perimanifest trial. We explore anticipated PIN-based inclusion rates from the preHD screening population and estimate sample-size requirements based on PIN threshold, trial duration, and outcome measure. Methods Individual participant data from ENROLL-HD were used to fit mixed effect linear models to assess longitudinal changes in clinical metrics for participants with early-manifest HD and PIN-stratified preHD subcohorts. Results A PIN threshold of 0.0 was met by 40% of the preHD participants in ENROLL-HD; 39.4% and 55.2% progressed to new diagnoses of early-manifest HD within 2 and 3 years, respectively. Various PIN thresholds also enabled the selection of specified ratios of prodromal preHD to early manifest HD participants for a perimanifest trial. Estimated sample sizes for a trial enrolling prodromal preHD (PIN > 0.0) and stage 1 and 2 motor-diagnosed participants varied depending on the composition of the screening pool, the length of follow-up (1, 2, or 3 years), and outcome measure. Conclusions The composition of a perimanifest clinical trial population can be defined using preselected PIN thresholds, facilitating the assessment of potential disease-modifying therapies in HD. (c) 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

We appreciate the comment by Kang et al. on our research.1 While we acknowledge findings of toxicity in a mouse model of elevated cellular dopamine due to overexpression of the dopamine transporter,2 such toxicity has not been observed in rodent or primate models of Parkinson disease (PD) in which the aromatic L-amino acid decarboxylase (AADC) gene therapy was tested.3,4 Moreover, in our observations of these participants 3 years after AADC therapy,1 we did not see evidence of significant clinical worsening, which would be expected if the AADC gene therapy was causing injury to medium spiny neurons.

To report final, 36-month safety and clinical outcomes from the PD-1101 trial of NBIb-1817 (VY-AADC01) in participants with moderately advanced Parkinson disease (PD) and motor fluctuations.PD-1101 was a phase 1b, open-label, dose escalation trial of VY-AADC01, an experimental AAV2 gene therapy encoding the human aromatic l-amino acid decarboxylase (AADC) enzyme. VY-AADC01 was delivered via bilateral, intraoperative MRI-guided putaminal infusions to 3 cohorts (n = 5 participants per cohort): cohort 1, ≤7.5 × 1011 vector genomes (vg); cohort 2, ≤1.5 × 1012 vg; cohort 3, ≤4.7 × 1012 vg.No serious adverse events (SAEs) attributed to VY-AADC01 were reported. All 4 non-vector-related SAEs (atrial fibrillation and pulmonary embolism in 1 participant and 2 events of small bowel obstruction in another participant) resolved. Requirements for PD medications were reduced by 21%-30% in the 2 highest dose cohorts at 36 months. Standard measures of motor function (PD diary, Unified Parkinson's Disease Rating Scale III "off"-medication and "on"-medication scores), global impressions of improvement (Clinical Global Impression of Improvement, Patient Global Impression of Improvement), and quality of life (39-item Parkinson's Disease Questionnaire) were stable or improved compared with baseline at 12, 24, and 36 months following VY-AADC01 administration across cohorts.VY-AADC01 and the surgical administration procedure were well-tolerated and resulted in stable or improved motor function and quality of life across cohorts, as well as reduced PD medication requirements in cohorts 2 and 3 over 3 years.NCT01973543.This study provides Class IV evidence that, in patients with moderately advanced PD and motor fluctuations, putaminal infusion of VY-AADC01 is well tolerated and may improve motor function.

To describe the patient burden of moderate-to-advanced Parkinson's disease (PD) stratified by Hoehn and Yahr (H&Y) stage.

The observational cross-sectional study was aimed to obtain information on the promotion and development of young professionals in Switzerland. An online survey with 20 questions was sent out. Data was collected on participants' demographic data, including age, gender, level of qualification, place of work, information on employment, future perspectives, and career prospects. The survey was sent out to 1920 practitioners, of which 440 (22.9%) responded (37.1% males and 62.9% females). Of them, 76.6% were members of the Swiss Dental Association (SSO) 15.9% students, and 7.5% non-SSO members. Most participants had parents with a dental education (80.9%), and 19.8% did not. Young dentists in Switzerland most often saw their career prospects as neutral (39.8%) or rather positive (39.3%). Whereas significantly fewer dentists had a negative view of their professional future (16.8%), including more women than men, the fewest dentists of both sexes (4.1%) saw their career prospects as positive by far. The majority of young dentists were satisfied with their career prospects. Within the limitations of the current study, the reasons for this need further investigation. Despite good career prospects, there is a desire among young colleagues for cantonal practice assistance and mentoring programs, as well as support in finding a job and in taking the plunge into self-employment.

Purpose: To evaluate a deep learning based image analysis software for the detection and localization of distal radius fractures. Method: A deep learning system (DLS) was trained on 524 wrist radiographs (166 showing fractures). Performance was tested on internal (100 radiographs, 42 showing fractures) and external WA sets (200 radiographs, 100 showing fractures). Single and combined views of the radiographs were shown to DLS and three readers. Readers were asked to indicate fracture location with regions of interest (ROI). The DLS yielded scores (range 0-1) and a heatmap. Detection performance was expressed as AUC, sensitivity and specificity at the optimal threshold and compared to radiologists' performance. Heatmaps were compared to radiologists' ROIs. Results: The DLS showed excellent performance on the internal test set (AUC 0.93 (95% confidence interval (CI) 0.82-0.98) - 0.96 (0.87-1.00), sensitivity 0.81 (0.58-0.95) - 0.90 (0.70-0.99), specificity 0.86 (0.68-0.96) - 1.0 (0.88-1.0)). DLS performance decreased on the external test set (AUC 0.80 (0.71-0.88) - 0.89 (0.81-0.94), sensitivity 0.64 (0.49-0.77) - 0.92 (0.81-0.98), specificity 0.60 (0.45-0.74) - 0.90 (0.78-0.97)). Radiologists' performance was comparable on internal data (sensitivity 0.71 (0.48-0.89) - 0.95 (0.76-1.0), specificity 0.52 (0.32-0.71) - 0.97 (0.82-1.0)) and better on external data (sensitivity 0.88 (0.76-0.96) - 0.98 (0.89-1.0), specificities 0.66 (0.51-0.79) - 1.0 (0.93-1.0), p < 0.05). In over 90%, the areas of peak activation aligned with radiologists' annotations. Conclusions: The DLS was able to detect and localize wrist fractures with a performance comparable to radiologists, using only a small dataset for training.

INTRODUCTION AND OBJECTIVE: Recurrence of urothelial carcinoma (UC) after radical cystectomy (RC) is associated with poor survival. Pelvic recurrences (PR) within the field of dissection are particularly concerning. The nature (soft tissue (ST), lymph node (LN) or undefinable) and spatial relation of PRs are not well described. We characterize the risk factors for LN and ST recurrence after RC and mapped their three-dimensional (3D) anatomic locations. METHODS: Between January 2000 to December 2014, 2257 bladder cancer patients underwent RC at MSKCC. We identified on imaging all first pelvic recurrences (first PR), defined as a mass initially presenting in the pelvis and or retroperitoneum (RP) below the inferior mesenteric artery (IMA) with or without distant metastasis. Using competing risk regression, we tested for association between a first PR and pathologic stage, LN status, ST and urothelial margin, variant histology, and preoperative chemotherapy (PC) against the risk of initial extrapelvic recurrence and death from other causes prior to recurrence. CT, MRI, and PET scans were referenced for location, size, and nature of PR, with results collated on a vascular and pelvis map. 3D volume-averaging was used to visualize recurrence risk and disease burden. RESULTS: 298 patients were found to have a first PR. Higher pathologic stage, positive LN, positive ST margin, and variant histology were associated with a higher risk of PR (p<0.0001 for all). PC was associated with higher risk of PR (p<0.0001), with highest risk in those who underwent chemotherapy with consolidation surgery (subhazard ratio = 3.01 95% CI 2.10, 4.31). The most frequent anatomic sites of LN recurrences (Figure) were the RP below the IMA (23%) and left common iliac artery (13%). ST recurrences were found near the bifurcation of left (30%) and right (26%) common iliac arteries. CONCLUSIONS: This study anatomically maps pelvic and lower RP recurrences after RC, found near vessel bifurcations, and certain vessels such as hypogastrics, common iliacs, and the aorta. First PR is associated with high risk pathologic features at RC and receipt of PC. This study can help identify sites vulnerable to in-field recurrence. 3D mapping may further elucidate the nature and frequency of PR and guide intraoperative or adjuvant therapy in patients at high risk for recurrence.Source of Funding: This work was supported by The Sidney Kimmel Center for Prostate and Urologic Cancers. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Proposal of a systematic approach to assess Deep infiltrating endometriosis (DIE) through pelvic Magnetic resonance imaging (MRI) using the Enzian classification and examination of inter-rater agreement. Three radiologists reviewed 23 MRI of patients with pelvic DIE at one tertiary referral center retrospectively and independently. Inclusion criteria were intraoperative confirmation of DIE and MR imaging according to ESUR (European Society of Urogenital Radiology) guidelines. Assessment of the anatomical pelvic compartments was performed using a manual based on the Enzian classification with step-by-step instructions using recommended planes and sequences presented here. Interrater agreement was measured using kappa statistics. According to the intraoperative site lesions in 53 anatomical compartments were present. Interrater agreement was best for compartments A (0.255) and FB (0.642). For FI (0.204) and B (0.146) it was slight, there was poor agreement for C (− 0.263), FA (− 0.022), and FO (− 0.030), respectively, and as for FU, no ureter infiltration was described. MRI as a noninvasive diagnostic tool offers essential advantages regarding classification and therapy planning for patients with DIE. However, its assessment is difficult and a more systematic approach is needed. Our proposed manual based on the Enzian classification is reproducible and could support radiologists and gynecologists.

Although relevant for assessment of sodium in multiple endocrine pathways, 23Na-T1 quantification is challenging due to technical limitations (SAR, B1 inhomogeneity) or influence of tissue’s local molecular dynamics. Hereby, we propose T1 quantification of 23Na-MRI signal acquired over the abdomen using a centric-reordered saturation-recovery (SR) true fast imaging with steady state precession (TrueFISP) sequence. Measurements were performed at 3T using a dual-tunable 23Na/1H coil in 7 healthy volunteers (TR/TE = 858–928/1.57 ms; flip angle = 90°; bandwidth = 450 Hz/px; voxel size = 5 × 5 × 10 mm3). Variable T1-weighting was achieved applying non-selective saturation pre-pulses delayed from the centre of the k-space acquisition by 25, 40, 60, 120 and 250 ms. T1-curve fitting was performed slice-wise, separately for average intensity values from the manually segmented areas of the renal parenchyma and spinal canal, over the increasing SR times- assuming monoexponential signal pattern. Mean ± standard deviation of 23Na-T1 was found as 29 ± 10 ms and 35 ± 8 ms for the renal parenchyma and the spinal canal, respectively. 23Na-T1 quantification using a SR-TrueFISP is feasible in clinical settings, in the images constrained by clinically applicable acquisition time of reduced spatial resolution or averages.

PurposeTo assess the associations between inter-site texture heterogeneity parameters derived from computed tomography (CT), survival, and BRCA mutation status in women with high-grade serous ovarian cancer (HGSOC).Materials and methodsRetrospective study of 88 HGSOC patients undergoing CT and BRCA mutation status testing prior to primary cytoreductive surgery. Associations between texture metricsnamely inter-site cluster variance (SCV), inter-site cluster prominence (SCP), inter-site cluster entropy (SE)and overall survival (OS), progression-free survival (PFS) as well as BRCA mutation status were assessed.ResultsHigher inter-site cluster variance (SCV) was associated with lower PFS (p=0.006) and OS (p=0.003). Higher inter-site cluster prominence (SCP) was associated with lower PFS (p=0.02) and higher inter-site cluster entropy (SE) correlated with lower OS (p=0.01). Higher values of all three metrics were significantly associated with lower complete surgical resection status in BRCA-negative patients (SE p=0.039, SCV p=0.006, SCP p=0.02), but not in BRCA-positive patients (SE p=0.7, SCV p=0.91, SCP p=0.67). None of the metrics were able to distinguish between BRCA mutation carrier and non-mutation carrier.ConclusionThe assessment of tumoral heterogeneity in the era of personalized medicine is important, as increased heterogeneity has been associated with distinct genomic abnormalities and worse patient outcomes. A radiomics approach using standard-of-care CT scans might have a clinical impact by offering a non-invasive tool to predict outcome and therefore improving treatment effectiveness. However, it was not able to assess BRCA mutation status in women with HGSOC.

INTRODUCTION AND OBJECTIVES: The role of preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in detecting lymph node metastases at radical cystectomy (RC) is unclear. Herein, we characterized the diagnostic properties of PET/CT for nodal metastases in patients with muscle-invasive urothelial carcinoma (MIUC) undergoing RC. METHODS: Dedicated genitourinary radiologist re-reviewed preoperative 18F-FDG PET/CT scans that were performed on patients with MIUC prior to RC between August 2012 and February 2017. PET/CT was routinely performed prior to RC at our institution during this study period. Findings on PET were considered positive if uptake was above the background blood pool uptake and not attributable to a physiologic or otherwise benign process. All patients underwent templated pelvic lymph node dissection with packeted node submission. This study included a mixed population of clinically relevant patient groups that were assessed as separate cohorts; patients were stratified by clinical node involvement (≥1cm short-axis on CT) and preoperative chemotherapy status. We assessed the diagnostic properties of PET/CT using sensitivity, specificity, positive predictive value, and negative predictive value. RESULTS: A total of 208 preoperative PET/CT scans (78 pre-chemotherapy, 61 post-chemotherapy, and 69 without chemotherapy) were performed on our cohort of 182 patients. The median time from PET/CT to surgery in those who did not receive chemotherapy was 28 days (IQR 15, 38). The rate of pathologic node positive (pN+) disease was 21.8% in clinically node negative (cN0) patients and 52.6% in clinically node positive (cN+) patients (including patients that received preoperative chemotherapy). In pN+ patients, the median metastatic focus size was 5mm. In cN0 patients, PET/CT rarely detected pN+ disease (sensitivity 7-23%) on a per patient or per region level regardless of chemotherapy status (Table 1). In cN+ patients, a negative PET/CT had utility in ruling out positive lymph node disease (sensitivity 92-100%, specificity 63-81%). CONCLUSIONS: The primary role of 18F-FDG PET/CT prior to RC appears to be in adjudicating enlarged nodes identified by CT. Preoperative 18F-FDG PET/CT has limited utility in cN0 patients and thus should not be used routinely. Table. No title available. Source of Funding: This research was supported by the Sidney Kimmel Center for Prostate and Urologic Cancers and funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

OBJECTIVE. For this study, we reviewed 56 standard-of-care CT examinations over a timespan of 2 years from patients with superior thoracic inlet venous obstruction and identified eight thoracic collateral pathways for venous blood return to the right heart. We evaluated each pathway individually from an anatomic and a pathophysiologic perspective for a better understanding of how such pathways form and what patterns can be expected. MATERIALS AND METHODS. All 56 patients were scanned according to our standard CT protocol. Images of the thoracic region were acquired in the craniocaudal direction during breath-holding using a second-generation dual-source CT scanner. Contrast medium was administered via a cubital or antecubital vein; the amount of contrast material ranged from 49 to 81 mL depending on patient body weight. RESULTS. Of the 56 patients, CT showed superior vena cava syndrome exclusively in 22 (39%) patients and showed superior vena cava syndrome and involvement of the left or right brachiocephalic vein or even the subclavian vein in the remaining 34 (61%) patients. We could not find any remarkable feature leading to the formation of only one collateral pathway or to a specific pattern depending on underlying cause or the level or the extent of obstruction. Thus, we believe that there are no specific patterns for how these venous detours form and that they are most probably driven by pressure gradients. CONCLUSION. Recognizing imaging findings associated with venous collateral pathways may prevent misdiagnosis or unnecessary follow-up examinations. Furthermore, knowledge of these collateral pathways and an understanding of the underlying cause can support interventional radiologists and vascular surgeons in planning interventional procedures and revascularization procedures.

The purpose of our study was to retrospectively evaluate and categorize temporal changes in MRI appearances of the prostate in patients who underwent focal therapy with MRI follow-up.

Purpose Neoadjuvant chemotherapy followed by radical cystectomy (RC) is a standard of care for the management of muscle-invasive bladder cancer (MIBC). Dose-dense cisplatin-based regimens have yielded favorable outcomes compared with standard-dose chemotherapy, yet the optimal neoadjuvant regimen remains undefined. We assessed the efficacy and tolerability of six cycles of neoadjuvant dose-dense gemcitabine and cisplatin (ddGC) in patients with MIBC. Patients and Methods In this prospective, multicenter phase II study, patients received ddGC (gemcitabine 2,500 mg/m2 on day 1 and cisplatin 35 mg/m2 on days 1 and 2) every 2 weeks for 6 cycles followed by RC. The primary end point was pathologic downstaging to non-muscle-invasive disease (< pT2N0). Patients who did not undergo RC were deemed nonresponders. Pretreatment tumors underwent next-generation sequencing to identify predictors of chemosensitivity. Results Forty-nine patients were enrolled from three institutions. The primary end point was met, with 57% of 46 evaluable patients downstaged to < pT2N0. Pathologic response correlated with improved recurrence-free survival and overall survival. Nineteen patients (39%) required toxicity-related dose modifications. Sixty-seven percent of patients completed all six planned cycles. No patient failed to undergo RC as a result of chemotherapy-associated toxicities. The most frequent treatment-related toxicity was anemia (12%; grade 3). The presence of a presumed deleterious DNA damage response (DDR) gene alteration was associated with chemosensitivity (positive predictive value for < pT2N0 [89%]). No patient with a deleterious DDR gene alteration has experienced recurrence at a median follow-up of 2 years. Conclusion Six cycles of ddGC is an active, well-tolerated neoadjuvant regimen for the treatment of patients with MIBC. The presence of a putative deleterious DDR gene alteration in pretreatment tumor tissue strongly predicted for chemosensitivity, durable response, and superior long-term survival.

18F-fluorodihydrotestosterone (18F-FDHT) is a radiolabeled analog of the androgen receptor's primary ligand that is currently being credentialed as a biomarker for prognosis, response, and pharmacodynamic effects of new therapeutics. As part of the biomarker qualification process, we prospectively assessed its reproducibility and repeatability in men with metastatic castration-resistant prostate cancer. Methods: We conducted a prospective multiinstitutional study of metastatic castration-resistant prostate cancer patients undergoing 2 (test/retest) 18F-FDHT PET/CT scans on 2 consecutive days. Two independent readers evaluated all examinations and recorded SUVs, androgen receptor-positive tumor volumes, and total lesion uptake for the most avid lesion detected in each of 32 predefined anatomic regions. The relative absolute difference and reproducibility coefficient (RC) of each metric were calculated between the test and retest scans. Linear regression analyses, intraclass correlation coefficients (ICCs), and Bland-Altman plots were used to evaluate repeatability of 18F-FDHT metrics. The coefficient of variation and ICC were used to assess interobserver reproducibility. Results: Twenty-seven patients with 140 18F-FDHT-avid regions were included. The best repeatability among 18F-FDHT uptake metrics was found for SUV metrics (SUVmax, SUVmean, and SUVpeak), with no significant differences in repeatability among them. Correlations between the test and retest scans were strong for all SUV metrics (R2 ≥ 0.92; ICC ≥ 0.97). The RCs of the SUV metrics ranged from 21.3% (SUVpeak) to 24.6% (SUVmax). The test and retest androgen receptor-positive tumor volumes and TLU, respectively, were highly correlated (R2 and ICC ≥ 0.97), although variability was significantly higher than that for SUV (RCs > 46.4%). The prostate-specific antigen levels, Gleason score, weight, and age did not affect repeatability, nor did total injected activity, uptake measurement time, or differences in uptake time between the 2 scans. Including the most avid lesion per patient, the 5 most avid lesions per patient, only lesions 4.2 mL or more, only lesions with an SUV of 4 g/mL or more, or normalizing of SUV to area under the parent plasma activity concentration-time curve did not significantly affect repeatability. All metrics showed high interobserver reproducibility (ICC > 0.98; coefficient of variation < 0.2%-10.8%). Conclusion: Uptake metrics derived from 18F-FDHT PET/CT show high repeatability and interobserver reproducibility.

To evaluate the associations between clinical outcomes and radiomics-derived inter-site spatial heterogeneity metrics across multiple metastatic lesions on CT in patients with high-grade serous ovarian cancer (HGSOC).

Purpose To investigate the diagnostic accuracy of sequential co-registered PET + MR (PET + MR) for local staging of malignant pleural mesothelioma (MPM) compared to PET/CT. Material and methods In a prospective clinical trial 34 consecutive patients (median age 66 years; range 40–79 years; 1 female, 33 male) with known MPM, who underwent PET/CT and PET + MR exams for either staging or re-staging/follow-up were evaluated. Imaging was conducted using a tri-modality PET/CT-MR set-up (Discovery PET/CT 690, 3T Discovery MR 750w, both GE Healthcare, Waukesha, WI, USA). In 26 cases histopathology served as standard of reference. Two independent readers evaluated images for T and N stage, confidence level (sure to unsure; 1–3) and subjective overall image quality (very good to non-diagnostic; 1–4). Inter-observer agreement of T and N stages (Cohen’s kappa) and interclass correlation coefficient (ICC) between PET/CT vs. PET + MR was calculated. Results Inter observer agreement for evaluation of T and N Stage in PET/CT images was excellent (k = 0.844 and k = 0.824, respectively), whereas PET + MR imaging showed substantial agreement in T and N stage (k = 0.729 and k = 0.691, respectively). The ICC of PET/CT vs. PET + MR for evaluation of both, T and N Stage, was excellent (ICC = 0.951 and ICC = 0.93, respectively). Diagnostic confidence was scored significantly higher in PET + MR compared to PET/CT (mean score = 1.66 and 1.93, respectively; p = 0.004). Image quality was diagnostic for all image series. Comparing pT and pN stage vs cT and cN stage (n = 26 cases), both imaging modalities showed excellent agreement for T stage (ICCPET+MR = 0.888 vs. ICCPET/CT = 0.853, respectively) and substantial to moderate agreement for N stage (ICCPET+MR = 0.683 vs. ICC = 0.595PET/CT, respectively). Conclusion Our findings suggest that diagnostic accuracy of PET + MR is comparable to PET/CT for local staging of MPM, whereas radiologists felt significantly more confident staging PET + MR compared to PET/CT images (p = 0003), using dedicated sequences.

[This corrects the article DOI: 10.1371/journal.pone.0167214.].